Shares of USANA Health Sciences, Inc. (NYSE:USNA) have been given an average recommendation of “Buy” by the seven research firms that are currently covering the stock, Marketbeat.com reports. Two research analysts have rated the stock with a hold recommendation, three have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $73.67.
Several brokerages have commented on USNA. Jefferies Financial Group initiated coverage on USANA Health Sciences in a research note on Thursday, August 22nd. They set a “hold” rating and a $65.00 target price on the stock. ValuEngine upgraded USANA Health Sciences from a “hold” rating to a “buy” rating in a research note on Tuesday. Finally, Zacks Investment Research raised USANA Health Sciences from a “hold” rating to a “strong-buy” rating and set a $86.00 price target on the stock in a report on Saturday, October 26th.
In other USANA Health Sciences news, Director Robert Auciaux sold 4,018 shares of the business’s stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $71.87, for a total transaction of $288,773.66. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Walter Noot sold 1,176 shares of the business’s stock in a transaction on Thursday, October 24th. The shares were sold at an average price of $75.98, for a total transaction of $89,352.48. Following the sale, the chief operating officer now owns 1,444 shares of the company’s stock, valued at $109,715.12. The disclosure for this sale can be found here. Insiders have sold a total of 8,385 shares of company stock worth $617,279 in the last 90 days. Company insiders own 42.50% of the company’s stock.
Shares of NYSE:USNA traded up $1.85 during trading on Friday, reaching $76.32. 102,627 shares of the stock traded hands, compared to its average volume of 229,211. The stock has a market cap of $1.59 billion, a P/E ratio of 14.79 and a beta of 0.30. The stock has a 50-day moving average of $73.55 and a two-hundred day moving average of $70.28. USANA Health Sciences has a 52-week low of $58.30 and a 52-week high of $125.61.
USANA Health Sciences (NYSE:USNA) last announced its quarterly earnings data on Tuesday, October 22nd. The company reported $1.09 earnings per share for the quarter, topping analysts’ consensus estimates of $0.87 by $0.22. The company had revenue of $260.60 million during the quarter, compared to analyst estimates of $256.22 million. USANA Health Sciences had a net margin of 9.38% and a return on equity of 27.60%. The firm’s revenue for the quarter was down 12.2% on a year-over-year basis. During the same period in the previous year, the business earned $1.24 EPS. Analysts predict that USANA Health Sciences will post 3.99 earnings per share for the current year.
About USANA Health Sciences
USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional and personal care products primarily to reduce the risk of chronic degenerative disease. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include low-glycemic meal replacement shakes, snack bars, and other related products, which provide macro-nutrition.
Featured Story: How to Trade Using Analysts Ratings
Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.